SeaStar Medical Holding Corp (ICU) stock: key figures, P/E, revenue and dividend

Health Care · United States · ISIN US81256L3024

Price
2.31 USD
Market cap
4.79 m USD
P/E (2025)
–
P/S (2025)
3.88
Dividend yield
0.00 %
Net margin
-984.60 %
Return on equity (ROE)
-116.65 %
Return on assets (ROA)
-85.82 %

SeaStar Medical Holding Corp financials

Fiscal year20242025
Revenue135,000.00 USD1.23 m USD
Gross profit135,000.00 USD1.18 m USD
Operating income-17.84 m USD-12.18 m USD
EBIT-24.68 m USD-12.44 m USD
Net income-24.83 m USD-12.15 m USD
Diluted EPS – continuing operations-6.63 USD–

Full history since 2020, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About SeaStar Medical Holding Corp

SeaStar Medical Holding Corporation, a commercial-stage healthcare company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, an SCD therapy that is in clinical trials for adult patients with AKI; and other products in various therapeutic areas, including cardiorenal syndrome, hepatorenal syndrome, and myocardial stunning in end-stage renal disease. SeaStar Medical Holding Corporation was founded in 2007 and is headquartered in Denver, Colorado.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 29.10.2026. Details in the risk notice.